IP Library Granted Patent US 9,163,068
Granted Patent B2
US 9,163,068 · App. 13/508,030 · Granted Oct 20, 2015

Influenza virus recombinant proteins

Inventors: Surender Khurana (Clarksburg, MD); Hana Golding (Rockville, MD)
Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health, Office of Technology Transfer
C07K14/005A61K39/12A61K39/145G01N33/559G01N33/56983A61K2039/55566C12N2760/16122C12N2760/16134G01N2333/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,163,068
App. No.
13/508,030
Granted
Oct 20, 2015
Kind
B2
Abstract

The present invention includes influenza Hemagglutinin protein fragments that fold properly when expressed in bacteria.

Claims (26)

1. A composition comprising oligomers of unglycosylated polypeptides, the polypeptides comprising:

a. at least a portion of an influenza Hemagglutinin-1 (HA-1) domain; and

b. lacking:

an Hemagglutinin-2 (HA-2) domain; or

both an Hemagglutinin-2 (HA-2) domain and an Hemagglutinin transmembrane domain;

wherein administration of the composition to an animal generates neutralizing antibodies against an influenza virus.

2. A physiological vaccine composition comprising,

the composition of claim 1 ; and

a physiological excipient.

3. The composition of claim 2 , further comprising an adjuvant.

4. A method of inducing an immune response against an influenza Hemagglutinin in an animal, the method comprising,

administering an amount of the composition of claim 2 to the animal sufficient to induce said immune response.

5. The composition of claim 1 , wherein said portion comprises an influenza amino acid sequence comprising the amino acids isoleucine (I) or leucine (L) at the amino acid corresponding to position 3, the amino acid cysteine (C) at the amino acid corresponding to position 4, the amino acids I, L, or valine (V) at the amino acid corresponding to position 5, and the amino acid glycine (G) at the amino acid corresponding to position 6 of SEQ ID NO:2.

6. The composition of claim 5 , wherein the polypeptide comprises a sequence of SEQ ID NO:1, 3, 4, 5, 6, or 7 or a sequence that corresponds to positions 1-259 of SEQ ID NO:2.

7. The composition of claim 5 , wherein the polypeptide binds to conformation sensitive influenza neutralizing antibodies.

8. The composition of claim 5 , wherein the amino acid sequence is at least 80% identical to positions 1-259 of SEQ ID NOS:1, 2, 3, 4, 5, 6, or 7.

9. The composition of claim 8 , wherein the portion comprises positions 1-259 of SEQ ID NOS:1, 2, 3, 4, 5, 6, or 7.

10. The composition of claim 5 , wherein the portion consists of an influenza amino acid sequence at least 80% identical to an amino acid sequence corresponding to positions 1-259 of SEQ ID NOS:1, 2, 3, 4, 5, 6, or 7.

11. The composition of claim 5 , wherein the portion comprises an influenza amino acid sequence corresponding to positions 1-320 of SEQ ID NOS:1, 2, 3,4 ,5, 6 or 7.

12. The composition of claim 11 , wherein the amino acid sequence comprises a sequence of SEQ ID NO:1, 3, 4, 5, 6, or 7 or a sequence that corresponds to positions 1-320 of SEQ ID NO:2.

13. The composition of claim 11 , wherein the amino acid sequence is at least 80% identical to positions 1-320 of SEQ ID NOS:1, 2, 3, 4, 5, 6, or 7.

14. The composition of claim 11 , wherein the portion comprises positions 1-320 of SEQ ID NOS:1, 2, 3, 4, 5, 6, or 7.

15. The composition of claim 11 , wherein the portion consists of an amino acid sequence at least 80% identical to positions 1-320 of SEQ ID NOS:1, 2, 3, 4, 5, 6, or 7.

16. The composition of claim 11 , wherein the portion consists of an influenza amino acid sequence at least 80% identical to an amino acid sequence corresponding to positions 1-320 of SEQ ID NOS:1, 2, 3, 4, 5, 6, or 7.

17. The composition of claim 5 , wherein the portion comprises an influenza amino acid sequence corresponding to positions 1-330 of SEQ ID NO:1.

18. The composition of claim 1 , wherein said portion comprises amino acids corresponding to positions 2 to 7 of SEQ ID NO:2 substituted into the corresponding positions of a heterologous HA1 polypeptide selected from: (a) SEQ ID NO:1, 3, 5, 6, or 7, or (b) a sequence that corresponds to positions 1 to 320 of SEQ ID NO:2.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2012
From: KHURANA, SURENDER; GOLDING, HANA
To: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH, OFFICE OF TECHNOLOGY TRANSFER
Reel/Frame 028783/0212 →
Continuity (3)
Provisional Application 61257785 · Nov 3, 2009
Provisional Application 61325216 · Apr 16, 2010
Related Publication 20120301504A1 · Nov 29, 2012